Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This filing is a Share Repurchase Report submitted by Takeda Pharmaceutical Company Limited for the reporting period from November 1, 2021, to November 30, 2021. The report was filed on December 14, 2021, pursuant to Rule 13a-16 of the Securities Exchange Act of 1934 and Article 24-6 of the Financial Instruments and Exchange Act of Japan.
Key Financial Metrics
The filing focuses exclusively on share repurchase activities and does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
- Total Repurchase Authorization: 35,000,000 shares (up to JPY 100,000,000,000) approved by the Board of Directors on October 28, 2021.
- Repurchase Period: November 2, 2021, to April 29, 2022.
- Shares Repurchased in Period: 15,335,700 shares.
- Total Amount Spent in Period: JPY 49,979,942,100.
- Progress of Repurchase: 43.82% of authorized shares; 49.98% of authorized amount.
- Treasury Shares Held (as of Nov 30, 2021): 15,511,118 shares.
- Total Issued Shares: 1,582,252,525 shares.
Material Changes
The filing details the execution of the share buyback program initiated in late October 2021. During November 2021, the company repurchased shares on 12 separate trading dates. The filing does not provide comparative data for the prior period to assess material changes in repurchase volume or pricing trends.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a statutory disclosure of share repurchase activity only.
Key Facts for Investor Verification
- Verify the average price per share paid during the November 2021 repurchase period (Total Amount / Total Shares).
- Confirm the remaining authorization balance (approx. 19.66 million shares or JPY 50 billion) available for repurchase through April 29, 2022.
- Note that treasury share counts exclude shares held by the ESOP trust account and the BIP trust account.
- Check subsequent filings to monitor the completion status of the repurchase program by the April 2022 deadline.